Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNCVIP)

Drug Name

4-MA Drug Info

Synonyms

4-Methylbenzoic acid; P-TOLUIC ACID; 99-94-5; 4-Toluic acid; Crithminic acid; p-Methylbenzoic acid; p-Toluylic acid; Benzoic acid, 4-methyl-; p-Carboxytoluene; para-Toluic acid; 4-Methyl-Benzoic Acid; Toluate; Toluenecarboxylic acid; p-Toluate; UNII-A26GBX5SSV; para toluic acid; NSC 2215; p-Toluic acid, 98%; EINECS 202-803-3; A26GBX5SSV; BRN 0507600; AI3-15627; CHEBI:36635; 2420-97-5 (cadmium salt); LPNBBFKOUUSUDB-UHFFFAOYSA-N; p-toluicacid; 4MA; Crithmic acid; rho-toluic acid; 4-Carboxytoluene; 4-MethylbenzoicAcid; 4-methylbenzic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 6917653
CAS Number: CAS 73671-86-0
TTD Drug ID: DMNCVIP

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hydroxysteroid dehydrogenase 3-beta (HSD3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-Sulfhydryl-Ethanol	DMJBO3D	Discovery agent	N.A.	Investigative	[3]
4-ANDROSTENE-3-17-DIONE	DMSE8NU	Discovery agent	N.A.	Investigative	[3]
Equilenin	DMHO56W	Discovery agent	N.A.	Investigative	[3]
5alpha-Androstan-3,17-Dione	DMHI7Y2	Discovery agent	N.A.	Investigative	[3]
17 beta-N,N-diethylcarbamoyl-4-aza-5 alpha-androstan-3-one (4MA)	DMDR1M6	Discovery agent	N.A.	Investigative	[4]
Epostane	DMV8PB4	Abortion	JA00	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Affected By 3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[6]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[7]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[8]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[9]
Dydrogesterone	DMAKIDV	Menstrual disorder	GA20.3	Approved	[10]
Hydroxyflutamide	DMGIZF5	Prostate cancer	2C82.0	Approved	[11]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[12]
Dutasteride	DMQ4TJK	Benign prostatic hyperplasia	GA90	Approved	[13]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[10]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hydroxysteroid dehydrogenase 3-beta (HSD3B)	TTZT9R2	3BHS1_HUMAN; 3BHS2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1)	OTQRET2B	S5A1_HUMAN	Gene/Protein Processing	[2]

------------------------------------------------------------------------------------

References

1	Activity and inhibition of 3-beta-hydroxysteroid dehydrogenase/delta-5-4-isomerase in human skin. Skin Pharmacol. 1997;10(3):160-8.
2	Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol. 1994 Mar;48(4):347-52.
3	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4	Inhibition of 3 beta-hydroxysteroid-dehydrogenase: an approach for prostate cancer treatment Anticancer Res. 1995 Jul-Aug;15(4):1349-54.
5	Termination of early pregnancy by the 3 beta-hydroxysteroid dehydrogenase inhibitor epostane. N Engl J Med. 1988 Sep 29;319(13):813-7.
6	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
7	Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
8	Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci. 2009 Dec;100(12):2459-64.
9	Effects of low dose treatment of tributyltin on the regulation of estrogen receptor functions in MCF-7 cells. Toxicol Appl Pharmacol. 2013 Jun 1;269(2):176-86.
10	Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
11	Androgen receptor modulation following combination exposure to brominated flame-retardants. Sci Rep. 2018 Mar 19;8(1):4843. doi: 10.1038/s41598-018-23181-0.
12	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
13	Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment. J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):129-40.
14	Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.